Qube Research & Technologies Ltd Invests $53.82 Million in Penumbra, Inc. $PEN

Qube Research & Technologies Ltd acquired a new position in shares of Penumbra, Inc. (NYSE:PEN - Free Report) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 209,710 shares of the company's stock, valued at approximately $53,818,000. Qube Research & Technologies Ltd owned approximately 0.54% of Penumbra as of its most recent filing with the Securities and Exchange Commission.3 Mid-Cap Medical Stocks Outperforming the MarketOther hedge funds also recently modified their holdings of the company. Vanguard Group Inc. grew its holdings in shares of Penumbra by 5.0% during the second quarter. Vanguard Group Inc. now owns 3,860,655 shares of the company's stock valued at $990,760,000 after buying an additional 185,306 shares in the last quarter. Geode Capital Management LLC boosted its position in Penumbra by 2.6% during the 2nd quarter. Geode Capital Management LLC now owns 706,404 shares of the company's stock worth $181,314,000 after acquiring an additional 17,772 shares during the period. JPMorgan Chase & Co. grew its stake in Penumbra by 437.0% during the 1st quarter. JPMorgan Chase & Co. now owns 703,634 shares of the company's stock valued at $188,159,000 after acquiring an additional 572,606 shares in the last quarter. Invesco Ltd. lifted its position in shares of Penumbra by 1,139.3% in the second quarter. Invesco Ltd. now owns 633,485 shares of the company's stock worth $162,571,000 after purchasing an additional 582,369 shares in the last quarter. Finally, Norges Bank acquired a new stake in shares of Penumbra during the second quarter worth approximately $114,014,000. Hedge funds and other institutional investors own 88.88% of the company's stock. Analysts Set New Price TargetsSeveral research firms have weighed in on PEN. BTIG Research reiterated a "buy" rating and issued a $320.00 price objective on shares of Penumbra in a research note on Monday, October 27th. Evercore ISI reaffirmed an "outperform" rating and issued a $286.00 price target on shares of Penumbra in a research note on Thursday, November 6th. Citigroup raised Penumbra from a "neutral" rating to a "buy" rating and lifted their price objective for the company from $285.00 to $350.00 in a research report on Thursday. Wells Fargo & Company started coverage on Penumbra in a research note on Tuesday, November 18th. They issued an "underweight" rating on the stock. Finally, Wall Street Zen downgraded Penumbra from a "buy" rating to a "hold" rating in a research note on Saturday, November 1st. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, Penumbra presently has a consensus rating of "Moderate Buy" and a consensus price target of $309.75.Are These Medical Device Makers Getting Ready To Rally? Check Out Our Latest Stock Analysis on PenumbraPenumbra Trading Up 3.0%Penumbra stock opened at $312.01 on Friday. Penumbra, Inc. has a one year low of $221.26 and a one year high of $314.74. The company's fifty day moving average price is $267.92 and its two-hundred day moving average price is $258.93. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.73 and a quick ratio of 4.18. The company has a market capitalization of $12.22 billion, a price-to-earnings ratio of 74.64, a PEG ratio of 2.50 and a beta of 0.66. Penumbra (NYSE:PEN - Get Free Report) last announced its quarterly earnings results on Wednesday, November 5th. The company reported $0.97 earnings per share for the quarter, topping analysts' consensus estimates of $0.90 by $0.07. The company had revenue of $354.69 million during the quarter, compared to analysts' expectations of $340.77 million. Penumbra had a return on equity of 11.35% and a net margin of 12.30%.The business's quarterly revenue was up 17.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.85 earnings per share. On average, analysts forecast that Penumbra, Inc. will post 3.67 earnings per share for the current fiscal year. Insider Buying and SellingIn related news, EVP Johanna Roberts sold 300 shares of the company's stock in a transaction on Friday, December 5th. The shares were sold at an average price of $300.13, for a total transaction of $90,039.00. Following the completion of the sale, the executive vice president directly owned 63,836 shares of the company's stock, valued at approximately $19,159,098.68. This represents a 0.47% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Arani Bose sold 7,500 shares of the firm's stock in a transaction on Tuesday, November 25th. The shares were sold at an average price of $300.19, for a total transaction of $2,251,425.00. Following the completion of the transaction, the director owned 275,261 shares in the company, valued at $82,630,599.59. The trade was a 2.65% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 19,744 shares of company stock worth $5,755,174. 4.20% of the stock is currently owned by insiders. Penumbra Company Profile (Free Report)Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.Further ReadingFive stocks we like better than PenumbraA Deeper Look at Bid-Ask Spreads3 Recently Downgraded Stocks to Avoid in 20263 Natural Gas Stocks That Offer Great Dividend YieldsThe Chip Boom Is Back: 3 Stocks Positioned for Huge GainsWhere Do I Find 52-Week Highs and Lows?Oracle Stock Hit Hard: Why Its AI Pipeline Could Drive a 2026 RallyThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Penumbra Right Now?Before you consider Penumbra, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Penumbra wasn't on the list.While Penumbra currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here